US · Healthcare · Biotechnology
EPS came in at -1.10 against a street estimate of -1.13 — a beat of 2.7%.
with an average price target of $35.33.
| Fund | Stake |
|---|---|
| FMR Inc | 10.78% |
| SR ONE CAPITAL MANAGEMENT, LP | 7.90% |
| TPG GP A, LLC | 7.68% |
| Lightspeed Management Co LLC | 7.51% |
| Orbimed Advisors LLC | 6.24% |
| Sanofi | 4.14% |
| Deerfield Management Co | 2.18% |
| Sands Capital Ventures, LLC | 1.82% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • For the nine months ended September 30, 2026, Odyssey Therapeutics reported a net loss of $144,109 thousand, compared with $115,13 | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Cash, cash equivalents and marketable securities were $387 million as of September 30, 2026, expected to fund operations into the s | 2026-11-04 |
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • Odyssey Therapeutics filed an 8-K on October 20, 2026, under Regulation FD. • The filing announced completed Phase 2a induction r | 2026-10-20 |
| Reg FD disclosure · Q3 2026 ODYSSEY THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • This is a Form 8-K filing dated September 8, 2026 — a current report disclosing material | 2026-09-09 |
| Quarterly report · Q2 2026 ODYSSEY THERAPEUTICS, INC. - 10-Q SUMMARY For Quarterly Period Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and marketable securities combined: | 2026-08-06 |
| Results announced · Q3 2026 ODYSSEY THERAPEUTICS - Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash on hand as of June 30, 2026: $433.1 million (expected to fund opera | 2026-08-04 |
| Reg FD disclosure · Q2 2026 ODYSSEY THERAPEUTICS, INC. – 8-K FILING SUMMARY HEADLINE NUMBERS • Company: Odyssey Therapeutics, Inc. (ticker: ODTX, traded on Nasdaq) • Filing Dat | 2026-06-23 |
| Quarterly report · Q1 2026 ODYSSEY THERAPEUTICS, INC. — 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash position: $35.7 million in cash and cash equivalents as of March 31, 202 | 2026-06-17 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Odyssey Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.